The FDA recently approved a new treatment option for the 2.7 million Americans living with atrial fibrillation – the most common type of cardiac arrhythmia in the U.S. The approval of St. Jude Medical’s TactiCath™ Quartz contact force ablation technology has significant implications for AF patients and their physicians-- which is especially important given more than 17 million people worldwide are projected to have AF by 2060. Over the last decade, cardiac ablation has emerged as a promising new treatment option for patients with AF. As the number of patients increase, it has never been more important to develop treatment solutions that increase the efficiency and effectiveness of ablation therapies. TactiCath is a new option for physicians that provides physicians with a real-time, objective measure of the force they apply to a patient’s heart wall during an ablation procedure . Without contact-force sensing technology, physicians have to estimate by touch with their hands the amount of force applied to the heart wall during an ablation. Click below to learn more about the TactiCath ablation catheter.
Posted on: Thu, 13 Nov 2014 23:30:12 +0000
Trending Topics
Recently Viewed Topics
© 2015